Johnson & Johnson lost another battle in its ongoing vaginal mesh litigation, as a California jury ordered the company to pay $5.6 million in the first trial over one of its mesh devices.
Boston Scientific advised physicians about a particular pacemaker in 2005--but then declined to pay the bills for those surgeries that it subsequently received from German health insurers. An EU court ruled on March 5 that the company is liable for those costs, according to Reuters.
Johnson & Johnson is ready to start trialing its Ebola vaccine in Africa, where Merck and NewLink are preparing to take theirs into Phase III. GlaxoSmithKline is also testing its jab there. But while thousands of healthcare workers have volunteered to participate in Ebola vaccine trials, the decision to mass-vaccinate against the disease is still up in the air.
Laboratory equipment and services company PerkinElmer announced that it will provide Johnson & Johnson's new San Francisco life science incubator with on-site staff, training and scientific application support.
The FDA has issued a Class 2 recall notice for an electrophysiology cardiac catheter from Biosense Webster, which is a Johnson & Johnson company, due to difficulties with retraction. The recall covers the Lasso NAV Duo Loop eco Catheters. Biosense Webster is the top-performing J&J medical device group as electrophysiology has gained traction of late.
Bloomberg TV 's Olivia Sterns asked the question on many people's minds when she asked the CEO of Dublin, OH-based Cardinal Health, George Barrett, why the drug wholesaler's purchase of devicemaker Cordis makes sense. "Where's the synergy?" she queried.
Nevro has taken another step toward embracing life as a public company a scant four months after its IPO. It is adding Brad Vale, the former head of Johnson & Johnson Development Company, to its board as of March 1.
Johnson & Johnson has opened the doors of its new biotech incubator, bringing in its first 10 resident startups and hoping to galvanize the next generation of life sciences innovators.
After months of speculation, Johnson & Johnson, the world's biggest maker of healthcare products, put the rumors to rest by confirming the sale of its Cordis vascular device unit to Cardinal Health for $1.9 billion. The deal is expected to be completed by the end of the year.
Johnson & Johnson has launched a health and wellness platform that's slated to function across all its businesses. The pan-corporate initiative launched with an example from its orthopedics player DePuy Synthes--the Patient Athlete program to help joint replacement patients better manage pain reduction before and after surgery.